Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
ACADEMIA
Academic Society Calls for Caution in Using Xofluza in Patients Under Age 12
The Japanese Association for Infectious Diseases (JAID) has issued a statement on the use of anti-influenza drugs urging doctors to use the cap-dependent endonuclease inhibitor Xofluza (baloxavir marboxil) with caution in patients under the age of 12. In clinical trials…
To read the full story
Related Article
- Xofluza Sees Sharp Sales Decline, but Inavir Logs Growth: 2019-2020 Flu Drug Market
May 13, 2020
- Shionogi Cuts Full-Year Guidance as Xofluza Sales Freefall
February 4, 2020
- Higher Rate of Resistance to Xofluza Seen in Younger Children: Shionogi
September 3, 2019
- Resistant Virus Found in Kids Administered Xofluza: NIID
January 28, 2019
ACADEMIA
- Consortium on Pediatric Drug Development Up and Running from This Fiscal Year
November 25, 2024
- Private-Academia Collab Yields 8 Pediatric Drug Approvals in Japan
November 8, 2024
- Alzheimer’s-Related Guidelines Being Revised to Accommodate Kisunla, Rexulti
November 6, 2024
- Japan Crafting Registry of All Hemophilia Patients, Company Use Eyed Too
November 5, 2024
- Pricing Partially to Blame for Diabetes Drug Shortage: Society Chair
November 5, 2024
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…